Martin-Loeches, Ignacio
Torres, Antoni
Nagavci, Blin
Aliberti, Stefano
Antonelli, Massimo
Bassetti, Matteo
Bos, Lieuwe D.
Chalmers, James D.
Derde, Lennie
de Waele, Jan
Garnacho-Montero, Jose
Kollef, Marin
Luna, Carlos M.
Menendez, Rosario
Niederman, Michael S.
Ponomarev, Dmitry
Restrepo, Marcos I.
Rigau, David
Schultz, Marcus J.
Weiss, Emmanuel
Welte, Tobias
Wunderink, Richard
Article History
Received: 12 April 2022
Accepted: 1 December 2022
First Online: 4 April 2023
Change Date: 17 May 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s00134-023-07082-z
Declarations
:
: IML reports grants from GE, consulting fees from Gilead and MSD, lecture honoraria from MSD, Gilead and Mundipharma, and advisory board and lectures for Pfizer, MSD and Menarini, outside the submitted work. AT reports consulting fees and lecture honoraria from Pfizer, Poliphor, MSD, Jansen and OM Pharma, and advisory board and lectures for Pfizer, MSD, Atriva, Jansen and Menarini, outside the submitted work. BN serves as the ERS methodologist. SA reports grants from Insmed Incorporated, Chiesi, and Fisher & Paykel, royalties from McGraw Hill, consulting fees from Insmed Incorporated, Insmed Italy, Insmed Ireland Ltd, Zambon, AstraZeneca UK Limited, CSL Behring GmbH, Grifols, Fondazione Charta, Boehringer Ingelheim, Chiesi, Zcube Srl, Menarini and MSD Italia Srl, lecture honoraria from GlaxoSmithKline Spa, and advisory board participation with Insmed Incorporated, Insmed Italy, AstraZeneca UK Limited and MSD Italia Srl, outside the submitted work. MA reports grants from GE, consulting fees from Gilead, lecture honoraria from MSD, Chiesi, Fisher & Pickel, and Orphan, and a leadership role at ESICM, outside the submitted work. MB reports research grants and/or advisor/consultant and/or speaker/chairman for Bayer, Biomerieux, Cidara, Cipla, Gilead, Menarini, MSD, Pfizer, Shionogi and Thermo-Fisher, outside the submitted work. LB reports grants from the Dutch Lung Foundation (young investigator grant), the Dutch Lung Foundation and Health Holland (public–private partnership grant), Dutch Lung Foundation (Dirkje Postma Award), IMI COVID-19 initiative and Amsterdam UMC fellowship, outside the submitted work. JC reports research grants from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Gilead Sciences, Grifols, Novartis and Insmed, and received consultancy or speaker fees from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Insmed, Janssen, Novartis, Pfizer and Zambon, outside the submitted work, and is chief editor of the ERJ. LD reports grants from European Union's FP7 grant PREPARE (602525); EU FP7-HEALTH-2013-INNOVATION-1, grant number 602525, H2020 RECOVER grant agreement number 101003589, ZonMw grant ANAkinra voor de behandeling van CORonavirus infectious disease 2019 op de Intensive Care (ANACOR-IC) project number 10150062010003, lecture honoraria from Netherlands International Sepsis Symposium, travel support from ESICM, ISICEM, Weimar sepsis Update, European Respiratory Society, Critical Care Reviews, UPMC Pittsburgh, International Sepsis Forum and ANZICS/ACCCN ASM, and advisory board participation with Sepsis Canada International; REMAP-CAP has received drugs as part of the trial interventions; and the following leadership positions: chair, international trial steering committee, REMAP-CAP (2021–present), coordinating committee member, ECRAID (2021–present), member expert panel on COVID-19 therapeutics, European Commission (2021–present), member “Pandemic Preparedness Plan” committee, KNAW (2021–present), chair elect Education and Training Committee (2019–2021), chair Clinical Training Committee, ESICM (2019–2021), task force infectious threats, NVIC (chair 2019–2021), outside the submitted work. JdW reports grants from Flanders Research Foundation and consulting fees from Pfizer and MSD, outside the submitted work. MK reports consulting fees from Merck, Pfizer and Shionogi, outside the submitted work. CL reports grants as principal investigator in clinical trials, has participated on adjudication committee for diagnosis in clinical trials, has received honoraria for lectures on pulmonary infections, has received economical support for attending to the ERS and ATS meetings, and has participated on an advisory board for pneumococcal vaccines, outside the submitted work. RM reports lecture honoraria from, and participated on advisory boards for Pfizer, Advanz Pharma, Gilead Sciences and GSK, and travel support from Pfizer, Gilead and Advanz Pharma, outside the submitted work. MN reports grants from Shionogi, Merck and Bayer, consulting fees from Pfizer, Merck, Shionogi, Bayer, Nabriva and Thermo-Fisher, and participation on an advisory board for Fab'entec, outside the submitted work. DR formerly served as ERS methodologist. MS received grants from Zonmw (Netherlands Organisation For Health Research And Development) and financial support from Hamilton Medical AG, Switzerland, outside of this project. EW reports speaker and travel fees from MSD, Akcea Therapeutics and LFB, outside the submitted work. TW reports grants from German Ministry of Research and Education, lecture honoraria from Advanz, Biotest, Thermo Fischer, MSD, Pfizer and Shionogi, outside the submitted work. RW reports consultancy and lectures for bioMerieux, and consultancy for MSD, Shionogi, LaJolla, Venatorx, Vir and Microbiotx, and has acted as chairman, clinical evaluation committee for Pfizer, and as DSMB member for Vir, outside the submitted work. All other authors have nothing to disclose.
Free to read: This content has been made available to all.